Research
Hormonal
RYGB leads to a significant reduction in the use of antihypertensive and antidiabetic medications, even in patients who do not achieve total disease remission.
Even if surgery does not completely cure your diabetes or high blood pressure, it often allows you to significantly reduce or stop taking your medications. This reduces the burden of polypharmacy and potential side effects, improving overall metabolic health.
ModerateSupportsMEDIUM confidence
Even in cases where there was no total remission of the diseases, there was a significant drop in the use of medicines used for their treatment.
Why this rating
Retrospective cohort data showing medication usage trends.
Source
The effect of Roux-en-Y gastric bypass in the treatment of hypertension and diabetes
Giulia Marchetti et al. · Revista do Colégio Brasileiro de Cirurgiões · 2020
DOI 10.1590/0100-6991e-20202655
cohort · n=252Cited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →